Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.

[1]  T. Heise,et al.  Improved Insulin Sensitivity With Angiotensin Receptor Neprilysin Inhibition in Individuals With Obesity and Hypertension , 2017, Clinical pharmacology and therapeutics.

[2]  S. Zraika,et al.  Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels , 2017, Diabetologia.

[3]  J. Buse,et al.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.

[4]  Lawrence A Leiter,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.

[5]  P. Pal,et al.  Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction , 2016, Cardiovascular therapeutics.

[6]  James Chamberlain,et al.  Diagnosis and Management of Diabetes: Synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes , 2016, Annals of Internal Medicine.

[7]  A. Tsapas,et al.  Empagliflozin , Cardiovascular Outcomes , and Mortality in Type 2 Diabetes , 2015 .

[8]  Akshay S. Desai,et al.  Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction , 2016, Circulation. Heart failure.

[9]  S. Solomon,et al.  Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. , 2015, The New England journal of medicine.

[10]  D. Joanisse,et al.  Defective Natriuretic Peptide Receptor Signaling in Skeletal Muscle Links Obesity to Type 2 Diabetes , 2015, Diabetes.

[11]  A. Shah,et al.  Cardiac Structure and Function Across the Glycemic Spectrum in Elderly Men and Women Free of Prevalent Heart Disease: The Atherosclerosis Risk In the Community Study , 2015, Circulation. Heart failure.

[12]  S. Solomon,et al.  Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme , 2015, European journal of heart failure.

[13]  M. Pencina,et al.  Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. , 2015, The New England journal of medicine.

[14]  M. Pfeffer,et al.  Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. , 2014, The lancet. Diabetes & endocrinology.

[15]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[16]  Akshay S. Desai,et al.  Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) , 2014, European journal of heart failure.

[17]  Deepak L. Bhatt,et al.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. , 2013, The New England journal of medicine.

[18]  M. Mogi,et al.  Role of renin–angiotensin–aldosterone system in adipose tissue dysfunction , 2013, Molecular and Cellular Endocrinology.

[19]  Chiadi E. Ndumele,et al.  NH2-Terminal Pro–Brain Natriuretic Peptide and Risk of Diabetes , 2013, Diabetes.

[20]  J. Jordan,et al.  Natriuretic peptides enhance the oxidative capacity of human skeletal muscle. , 2012, Journal of Clinical Investigation.

[21]  M. Mori,et al.  Kinin B1 Receptor in Adipocytes Regulates Glucose Tolerance and Predisposition to Obesity , 2012, PloS one.

[22]  G. Pacini,et al.  B-type natriuretic peptide (BNP) affects the initial response to intravenous glucose: a randomised placebo-controlled cross-over study in healthy men , 2012, Diabetologia.

[23]  F. Sweep,et al.  Atrial Natriuretic Peptide Induces Postprandial Lipid Oxidation in Humans , 2008, Diabetes.

[24]  M. Pfeffer,et al.  The Hemoglobin A 1 c Level as a Progressive Risk Factor for Cardiovascular Death , Hospitalization for Heart Failure , or Death in Patients With Chronic Heart Failure , 2008 .

[25]  Salim Yusuf,et al.  Predictors of mortality and morbidity in patients with chronic heart failure. , 2006, European heart journal.

[26]  J. Holst,et al.  Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig , 2005, Diabetologia.

[27]  J. Jordan,et al.  Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. , 2005, The Journal of clinical endocrinology and metabolism.

[28]  M. Pfeffer,et al.  VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context , 2003, European journal of heart failure.

[29]  J. Rouleau,et al.  Vasopeptidase Inhibitor Omapatrilat Induces Profound Insulin Sensitization and Increases Myocardial Glucose Uptake in Zucker Fatty Rats: Studies Comparing a Vasopeptidase Inhibitor, Angiotensin-Converting Enzyme Inhibitor, and Angiotensin II Type I Receptor Blocker , 2003, Circulation.

[30]  B. Roques,et al.  Effects of Dual Angiotensin-Converting Enzyme and Neutral Endopeptidase 24-11 Chronic Inhibition by Mixanpril on Insulin Sensitivity in Lean and Obese Zucker Rats , 2003, Journal of cardiovascular pharmacology.

[31]  D. Coates,et al.  The neprilysin (NEP) family of zinc metalloendopeptidases: Genomics and function , 2001, BioEssays : news and reviews in molecular, cellular and developmental biology.

[32]  F. Messerli,et al.  Angiotensin II receptor inhibition. A new therapeutic principle. , 1996, Archives of internal medicine.

[33]  B. Mitchell.  Predictors for mortality. , 1995, Archives of disease in childhood. Fetal and neonatal edition.

[34]  K. Uekama,et al.  Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. , 1995, Clinical chemistry.

[35]  Z. Freedman,et al.  Protein glycosylation in diabetes mellitus: a review of laboratory measurements and of their clinical utility. , 1983, Clinica chimica acta; international journal of clinical chemistry.